Chordia Therapeutics Valuation

Is 190A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 190A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 190A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 190A's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 190A?

Key metric: As 190A is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 190A. This is calculated by dividing 190A's market cap by their current book value.
What is 190A's PB Ratio?
PB Ratio	4x
Book	JP¥4.16b
Market Cap	JP¥16.85b

190A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 190A's PB Ratio compare to its peers?

The above table shows the PB ratio for 190A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.7x
4575 CanBas	5.4x	n/a	JP¥17.0b
4593 Healios K.K	5.6x	35.2%	JP¥17.7b
4588 Oncolys BioPharma	8.4x	n/a	JP¥16.0b
7774 Japan Tissue Engineering	3.4x	51.1%	JP¥20.1b
190A Chordia Therapeutics	4x	n/a	JP¥16.9b

Price-To-Book vs Peers: 190A is good value based on its Price-To-Book Ratio (4x) compared to the peer average (5.7x).

Price to Book Ratio vs Industry

How does 190A's PB Ratio compare vs other companies in the JP Biotechs Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
2342 Transgenic Group	0.6x	n/a	US$21.32m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 190A is expensive based on its Price-To-Book Ratio (4x) compared to the JP Biotechs industry average (3.6x).

Price to Book Ratio vs Fair Ratio

What is 190A's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

190A PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 190A's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,094.50

-2.1%

-10.9%

Tsumura

JP¥368.9b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,858.00

1.2%

76.3%

ASKA Pharmaceutical HoldingsLtd

JP¥57.7b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,036.00

-2.2%

13.1%